Quick Answer
CASI Pharmaceuticals, Inc. reported Stockholders Equity of $1.85 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $1.85M | -92.3% |
| 2023 | $24.16M | -45.8% |
| 2022 | $44.57M | -47.3% |
| 2021 | $84.50M | +3.6% |
| 2020 | $81.54M | +11.7% |
| 2019 | $73.00M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -92.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2024 period, CASI Pharmaceuticals, Inc.’s stockholders equity has declined by 97.5% (from $73.00 million to $1.85 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: